Long circulating nanoparticles for sustained release of therapeutic agents
AssigneeBIND Therapeutics, Inc.
InventorsStephen E. Zale, Greg Troiano, Mir M. Ali, Jeff Hrkach, James Wright
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.
Claims12
A sterile, biocompatible, injectable nanoparticle composition comprising a plurality of long circulating nanoparticles having a diameter of about 70 to about 130 nm, each of the plurality of the long circulating nanoparticles comprising:
- about 70 to about 90 weight percent poly(lactic) acid-co-poly(ethylene) glycol, wherein the weight ratio of poly(lactic) acid to poly(ethylene) glycol is about 15 kDa/2 kDa to about 20 kDa/10 kDa, and
- a therapeutic agent encapsulated in the nanoparticles,
- said composition providing an elevated plasma concentration of the therapeutic agent for at least 24 hours when the composition is administered to a patient, to provide:
- an area under the plasma concentration time curve (AUC) that is increased by at least 500% over the AUC provided when the equivalent dosage of the therapeutic agent is intravenously administered in a non-nanoparticle to a patient;
- an actual peak plasma concentration (Cmax) that is at least 100% higher as compared to a Cmax of said therapeutic when the therapeutic agent is intravenously administered in a non-nanoparticle to the patient;
- and
- a volume of distribution (Vz) that is about the patient's plasma volume upon intravenous administration of the composition.
A sterile, biocompatible, injectable nanoparticle composition comprising a plurality of long circulating nanoparticles, each long circulating nanoparticle comprising:
- about 70 to about 90 weight percent of an α-hydroxy polyester-co-polyether comprising a weight ratio of about 16/5 polylactic acid-polyethylene glycol, and docetaxel, said composition providing an elevated plasma concentration of docetaxel for at least 24 hours when the composition is administered to a patient.
Dependencies are inferred from the claim text.